Our Partners
News
Our Technologies
AI Antibody Discovery Platform
MOLCURE’s Core Technology and Strengths
Core Technology
- An evolving AI platform with an in-house rapid learning loop
- Specialized algorithms for building AI suitable for biological data
Strengths
- Proprietary Antibody LLM: Large Language Model build from scratch
- Proprietary Database: Over 1 billion proprietary datapoints, Antibody / Peptide
- Wet lab: Directed Evolution Experiment, Next Generation Sequencer
Company Presentation by our CEO/CSO, Dr. Tamaki (at PEGS Boston 2025)
For details, please see here.
How We Collaborate
Screening, NGS, and AI Analysis
For partners seeking end-to-end support in AI-driven molecular design, including high-throughput screening, next-generation sequencing (NGS), and advanced AI analysis.
AI-Powered de novo Discovery
For partners aiming to discover novel molecules from their samples using MOLCURE’s proprietary AI technologies.
AI-Driven Lead Optimization
For partners who wish to optimize their own candidate molecules through MOLCURE’s AI-based lead optimization platform.
Consulting-Based Problem Solving
For partners looking for expert guidance on leveraging AI technologies to accelerate and enhance their drug discovery processes.
Please feel free to contact us.
About Us
Satoshi Tamaki, Ph.D.
CEO / CSO
Ryu Ogawa, Ph.D.
CIO / Founder
Natsumi Negishi
CFO
Batsergelen Myagmar, Ph.D.
CAIO
Han Lim, Ph.D., MBBS
Senior Advisor
Koichi Takahashi, Ph.D.
Senior Advisor
Kengo Miura
External director
Tatsuo Tsutsumi
External director
Hiroshi Abe
Statutory auditor